-
Arnold and colleagues at Barnes-Jewish Hospital in St. Louis performed a 6-year retrospective cohort study of patients with bronchoalveolar lavage (BAL) documented ventilator-associated pneumonia (VAP), diagnosed by accepted clinical and quantitative culture criteria, that was caused by either Pseudomonas aeruginosa (PA) and Acinetobacter baumannii(AB).
-
This paper reports on the findings of a systematic literature review on noise and noise-reduction strategies in the intensive care unit (ICU).
-
Patients have referred to receiving mechanical ventilatory support as, "the most inhumane ever experienced".... While mechanical ventilation is one of the most commonly used treatment modalities in the ICU, this life-saving modality causes great anxiety, distress, and discomfort in patients.
-
In this issue: New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
-
This is a report of a secondary analysis of data from the original Acute Respiratory Distress Syndrome (ARDS) Network low-tidal-volume study, which demonstrated improved survival with ventilator tidal volumes of 6 (vs 12) mL/kg predicted body weight in patients meeting the American-European consensus definition of acute lung injury (ALI) or ARDS.
-
The purpose of this article was to apply aviation communication principles and strategies to the field of critical care medicine, particularly crisis communication situations.
-
This study was a secondary analysis of data from an earlier randomized clinical trial comparing one antibiotic vs two (meropenem alone or meropenem plus ciprofloxacin) as early empiric therapy for ventilator-associated pneumonia (VAP).
-
Hemodynamic monitoring is an essential part of caring for critically ill patients. Critical care providers are regularly faced with the challenge of determining whether a patient is adequately volume resuscitated, and hemodynamic assessments are often the first step in making a proper diagnosis so that other life-saving therapies can be promptly implemented.
-
In this issue: New indication for rivaroxaban; new study on warfarin testing; medications causing adverse drug events; niacin as an add-on therapy; and FDA actions.